Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) CEO James Lanthier and Chief Scientific Officer Joseph Araujo tell Proactive it has filed a new provisional patent application covering new chemical entities (NCEs) that expand the company's next-generation DMT and 5-MeO-DMT, or 'Family 4', platform, currently under development. The company said the new patent application exemplifies its corporate strategy to broaden the therapeutic psychedelic toolbox for patients with mental health disorders who are waiting for transformative medicines and covers novel chemical space while maintaining the functionality of traditional psychedelics.
Mindset Pharma strengthens IP portfolio with new provisional patent application
